The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD-LC patients were retrospectively investigated. Four patients, who ...
In aqueous solution containing FA-BSA and carboplatin in the magnetic rotor, and then place it on the constant temperature magnetic stirrer, uniform rotation mixing FA-BSA and carboplatin aqueous solution, using micro-peristaltic pump at the right speed to FA-BSA drops plus paclitaxel and carboplat...
To examine the toxicity profile and antineoplastic activity of carboplatin (area under the concentration-time curve of 4 to 7.5) plus 3-hour infusional paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (135 or 175 mg/m2) in women with advanced gynecologic malignancies, we retrospect...
Transcript:Edward S. Kim, MD, FACP:And so, when you come to nab-paclitaxel and how they’ve most recently done with Mark Socinski’s study, the phase III study, the first thing people said was, ‘Well, it’s still Taxol. You’re just changing the delivery, whether it’s albumin-b...
The aim of phase Ib was to evaluate the tolerance and safety of neoadjuvant nab-paclitaxel plus carboplatin in patients with stage III-IV, unresectable OC; phase II aimed at determining the efficacy and safety of this combination in the overall population. The study was conducted in accordance ...
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemei... Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. ...
For patients whose cancer was pMMR, median progression-free survival (PFS) in the KEYTRUDA plus carboplatin and paclitaxel arm was 11.1 months (95% CI, 8.7-13.5) versus 8.5 months (95% CI, 7.2-8.8) for the placebo plus carbop...
We aimed to evaluate the efficacy and safety of carboplatin plus weekly paclitaxel with bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients with stage IIIB/IV or postoperative recurrent NSCLC (n=33) were treated with carboplatin (area under the curve of...
Methods: In this double-blind, multicenter, phase III trial, previously untreated pts with histologically or cytologically confirmed stage IIIB-IV squamous NSCLC were randomized 1:1 to receive 4–6 cycles of carboplatin (AUC 5) plus paclitaxel (175 mg/m2) with camrelizumab (200 mg) or plac...